Table 1: Adverse Reactions Reported by 2% or More of Children (6 to 12 Years Old) Receiving Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules with Higher Incidence Than on Placebo in a 584 Patient Clinical Study
| Body System | Preferred Term | Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules (n=374) | Placebo (n=210) |
|---|
| General | Abdominal Pain (stomachache) Fever Infection Accidental Injury Asthenia (fatigue) | 14% 5% 4% 3% 2% | 10% 2% 2% 2% 0% |
| Digestive System | Loss of Appetite Vomiting Nausea Dyspepsia | 22% 7% 5% 2% | 2% 4% 3% 1% |
| Nervous System | Insomnia Emotional Lability Nervousness Dizziness | 17% 9% 6% 2% | 2% 2% 2% 0% |
| Metabolic/ Nutritional | Weight Loss | 4% | 0% |
Table 2: Adverse Reactions Reported by 5% or More of Adolescents (13 to 17 Years Old) Weighing ≤ 75 kg/165 lbs Receiving Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules with Higher Incidence Than Placebo in a 287 Patient Clinical Forced Weekly-Dose Titration Study*
| Body System | Preferred Term | Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules (n=233) | Placebo (n=54) |
| General | Abdominal Pain (stomachache) | 11% | 2% |
| Digestive System | Loss of Appetiteb | 36% | 2% |
| Nervous System | Insomniab Nervousness | 12% 6% | 4% 6%a |
| Metabolic/Nutritional | Weight Lossb | 9% | 0% |
Note: The following reactions did not meet the criterion for inclusion in Table 2 but were reported by 2 to 4% of adolescent patients receiving dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules with a higher incidence than patients receiving placebo in this study: accidental injury, asthenia (fatigue), dry mouth, dyspepsia, emotional lability, nausea, somnolence, and vomiting.
*Included doses up to 40 mg
a Appears the same due to rounding
b Dose-related adverse reactions
Table 3: Adverse Reactions Reported by 5% or More of Adults Receiving Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules with Higher Incidence Than on Placebo in a 255 Patient Clinical Forced Weekly-Dose Titration Study*
| Body System | Preferred Term | Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules (n=191) | Placebo (n=64) |
|---|
| General | Headache Asthenia | 26% 6% | 13% 5% |
| Digestive System | Dry Mouth Loss of Appetite Nausea Diarrhea | 35% 33% 8% 6% | 5% 3% 3% 0% |
| Nervous System | Insomnia Agitation Anxiety Dizziness Nervousness | 27% 8% 8% 7% 13% | 13% 5% 5% 0% 13%a |
| Cardiovascular System | Tachycardia | 6% | 3% |
| Metabolic/Nutritional | Weight Loss | 10% | 0% |
| Urogenital System | Urinary Tract Infection | 5% | 0% |
Note: The following reactions did not meet the criterion for inclusion in Table 3 but were reported by 2 to 4% of adult patients receiving dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules with a higher incidence than patients receiving placebo in this study: infection, photosensitivity reaction, constipation, tooth disorder (e.g., teeth clenching, tooth infection), emotional lability, libido decreased, somnolence, speech disorder (e.g., stuttering, excessive speech), palpitation, twitching, dyspnea, sweating, dysmenorrhea, and impotence.
*Included doses up to 60 mg.
aAppears the same due to rounding
Hypertension
In a controlled 4 week outpatient clinical study of adolescents with ADHD, isolated systolic blood pressure elevations ≥15 mmHg were observed in 7/64 (11%) placebo-treated patients and 7/100 (7%) patients receiving dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules 10 or 20 mg. Isolated elevations in diastolic blood pressure ≥ 8 mmHg were observed in 16/64 (25%) placebo-treated patients and 22/100 (22%) dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsule-treated patients. Similar results were observed at higher doses [see Warnings and Precautions (5.2)].
In a single-dose pharmacokinetic study in 23 adolescents with ADHD, isolated increases in systolic blood pressure (above the upper 95% CI for age, gender, and stature) were observed in 2/17 (12%) and 8/23 (35%), subjects administered 10 and 20 mg dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, respectively. Higher single doses were associated with a greater increase in systolic blood pressure. All increases were transient, appeared maximal at 2 to 4 hours post dose and not associated with symptoms.